New hope for glioblastoma? drug combo trial launches
NCT ID NCT05986851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug azeliragon, taken as a capsule, together with radiation therapy for people with a specific type of glioblastoma (a fast-growing brain cancer). The study includes 30 participants whose tumors lack a certain DNA marker (MGMT unmethylated). The goal is to see if the combination is safe and can slow cancer growth or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azeliragon (oral capsule)
What this could lead to
If successful, this could point toward a new treatment option for a hard-to-treat form of glioblastoma, potentially slowing cancer growth and extending survival.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply widely. The drug may not prove effective or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Corewell Health
Royal Oak, Michigan, 48073, United States
-
Lenox Hill Hospital
New York, New York, 10021, United States
-
Miami Cancer Institute - Baptist Health
Miami, Florida, 33176, United States
-
The University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Utah Health Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
University of Washington
Seattle, Washington, 98109, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110, United States